PMID- 32087232
OWN - NLM
STAT- MEDLINE
DCOM- 20200527
LR  - 20200527
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 249
DP  - 2020 May 15
TI  - Early astragaloside IV administration attenuates experimental autoimmune 
      encephalomyelitis in mice by suppressing the maturation and function of dendritic 
      cells.
PG  - 117448
LID - S0024-3205(20)30196-X [pii]
LID - 10.1016/j.lfs.2020.117448 [doi]
AB  - AIMS: Dendritic cells (DCs) actively participate in the pathogenesis of multiple 
      sclerosis (MS), an autoimmune disease. Astragaloside IV (ASI), an active monomer 
      isolated from the Chinese medicine Astragalus membranaceus, has a wide range of 
      pharmacological effects. We aimed to elucidate the effects of ASI on the 
      development of DCs in the early stage of MS/EAE. MAIN METHODS: The mice were 
      administered with ASI (20 mg/kg) daily 3 days in advance of EAE induction and 
      continuously until day 7 post-immunization. The effect of ASI on CD11c(+) DC 
      cells from bone marrow (BMDCs) or the spleen of EAE mice at day 7 
      post-immunization were investigated respectively by flow cytometry, ELISA, 
      western blot, real-time PCR and immunofluorescence. KEY FINDINGS: ASI 
      administration in the early stage of EAE was demonstrated to delay the onset and 
      alleviate the severity of the disease. ASI inhibited the maturation and the 
      antigen presentation of DCs in spleen of EAE mice and LPS-stimulated BMDCs, as 
      evidenced by decreased expressions of CD11c, CD86, CD40 and MHC II. Accordingly, 
      DCs treated by ASI secreted less IL-6 and IL-12, and prevented the 
      differentiation of CD4(+) T cells into Th1 and Th17 cells, which was probably 
      through inhibiting the activation of NFkappaB and MAPKs signaling pathways. 
      SIGNIFICANCE: Our results implicated the alleviative effect of early ASI 
      administration on EAE might be mediated by suppressing the maturation and 
      function of DCs. The novel findings may add to our knowledge of ASI in the 
      potentially clinical treatment of MS.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Yang, Liu
AU  - Yang L
AD  - Shanghai Key Laboratory of Compound Chinese Medicines, The Ministry of Education 
      (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of 
      Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 
      Shanghai 201203, China.
FAU - Han, Xinyan
AU  - Han X
AD  - Shanghai Key Laboratory of Compound Chinese Medicines, The Ministry of Education 
      (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of 
      Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 
      Shanghai 201203, China.
FAU - Yuan, Jinfeng
AU  - Yuan J
AD  - Shanghai Key Laboratory of Compound Chinese Medicines, The Ministry of Education 
      (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of 
      Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 
      Shanghai 201203, China.
FAU - Xing, Faping
AU  - Xing F
AD  - Shanghai Key Laboratory of Compound Chinese Medicines, The Ministry of Education 
      (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of 
      Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 
      Shanghai 201203, China.
FAU - Hu, Zhixing
AU  - Hu Z
AD  - Shanghai Key Laboratory of Compound Chinese Medicines, The Ministry of Education 
      (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of 
      Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 
      Shanghai 201203, China.
FAU - Huang, Fei
AU  - Huang F
AD  - Shanghai Key Laboratory of Compound Chinese Medicines, The Ministry of Education 
      (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of 
      Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 
      Shanghai 201203, China.
FAU - Wu, Hui
AU  - Wu H
AD  - Shanghai Key Laboratory of Compound Chinese Medicines, The Ministry of Education 
      (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of 
      Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 
      Shanghai 201203, China.
FAU - Shi, Hailian
AU  - Shi H
AD  - Shanghai Key Laboratory of Compound Chinese Medicines, The Ministry of Education 
      (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of 
      Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 
      Shanghai 201203, China.
FAU - Zhang, Ting
AU  - Zhang T
AD  - Classical Prescription Experimental Platform, Shanghai University of Traditional 
      Chinese Medicine, Shanghai 201203, China. Electronic address: 
      zhangtingdoctor@163.com.
FAU - Wu, Xiaojun
AU  - Wu X
AD  - Shanghai Key Laboratory of Compound Chinese Medicines, The Ministry of Education 
      (MOE) Key Laboratory for Standardization of Chinese Medicines, Institute of 
      Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, 
      Shanghai 201203, China. Electronic address: xiaojunwu320@126.com.
LA  - eng
PT  - Journal Article
DEP - 20200219
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Cytokines)
RN  - 0 (NF-kappa B)
RN  - 0 (Saponins)
RN  - 0 (Triterpenes)
RN  - 3A592W8XKE (astragaloside A)
SB  - IM
MH  - Animals
MH  - Coculture Techniques
MH  - Cytokines/biosynthesis
MH  - Dendritic Cells/cytology/*drug effects/metabolism
MH  - Encephalomyelitis, Autoimmune, Experimental/pathology/*prevention & control
MH  - Female
MH  - MAP Kinase Signaling System
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - NF-kappa B/metabolism
MH  - Saponins/*administration & dosage/pharmacology
MH  - Severity of Illness Index
MH  - Triterpenes/*administration & dosage/pharmacology
OTO - NOTNLM
OT  - Astragaloside IV
OT  - Dendritic cells
OT  - Experimental autoimmune encephalomyelitis
OT  - Maturation and function
OT  - Multiple sclerosis
COIS- Declaration of competing interest We declare that we do not have any commercial 
      or associative interest that represents a conflict of interest in connection with 
      the work submitted.
EDAT- 2020/02/23 06:00
MHDA- 2020/05/28 06:00
CRDT- 2020/02/23 06:00
PHST- 2019/11/29 00:00 [received]
PHST- 2020/02/15 00:00 [revised]
PHST- 2020/02/17 00:00 [accepted]
PHST- 2020/02/23 06:00 [pubmed]
PHST- 2020/05/28 06:00 [medline]
PHST- 2020/02/23 06:00 [entrez]
AID - S0024-3205(20)30196-X [pii]
AID - 10.1016/j.lfs.2020.117448 [doi]
PST - ppublish
SO  - Life Sci. 2020 May 15;249:117448. doi: 10.1016/j.lfs.2020.117448. Epub 2020 Feb 
      19.